Anika Therapeutics Announces U.S. Distribution Agreement for Advanced Wound Care Product

Anika Therapeutics, Inc. ANIK, a leader in products for tissue protection, healing, and repair, based on hyaluronic acid technology, today announced Anika Therapeutics S.r.l., its wholly owned subsidiary, has entered into a new, five-year exclusive U.S. distribution agreement with Misonix, Inc. MSON, which will distribute and sell Anika's Hyalomatrix^®—an FDA-approved, HA-based skin substitute. One of the numerous products added to the Anika portfolio through its acquisition of Fidia Advanced Biopolymers (now Anika Therapeutics S.r.l.), Hyalomatrix is indicated for treatment of a wide range of acute and chronic wounds.